MDT vs SENS
MDT: Medtronic is a global healthcare technology leader dedicated to alleviating pain, restoring health, and extending life through innovative medical devices and digital solutions. SENS: Senseonics develops and markets long-term, implantable continuous glucose monitoring systems designed to simplify diabetes management for patients.
Side-by-side fundamentals
| Metric | MDT | SENS | Edge |
|---|---|---|---|
| Price as of 2026-10-08 close | $87.75 | $9.02 | |
| Market cap | $112.2B | $477M | |
| P/E as of 2026-10-08 | 23.54 | n/a | |
| PEG as of 2026-10-08, 3-year EPS CAGR to FY2026 | 2.41 | n/a | |
| Net margin | +13.2% | -196.0% | MDT higher |
| Gross margin FY2025, SEC XBRL | n/a | +44.7% | |
| Operating margin | +17.8% | -193.8% | MDT higher |
| ROE | +9.7% | -113.2% | MDT higher |
| ROA | +5.2% | -54.7% | MDT higher |
| Debt / equity as of 2026-09-03 | 0.57 | 0.62 | MDT lower |
| Revenue growth (YoY) as of 2026-09-03 | +8.4% | +90.6% | SENS higher |
| Revenue CAGR (3y) SEC XBRL | +5.2% | +29.1% | SENS higher |
| Dividend yield as of 2026-09-03 | +3.1% | n/a | |
| Dividend streak (yrs) SEC XBRL | 14 | 0 | MDT higher |
| Beta as of 2026-09-03 | 0.36 | 1.90 | |
| 1-year return as of 2026-10-08 close | -10.3% | -2.4% | SENS higher |
Fundamentals: SEC XBRL company filings for the figures marked with a fiscal year, and market data, as of 2026-09-03 for the rest. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-10-08.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.